<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="../../external.html?link=http://www.w3.org/1999/xhtml"><head><title>Issues Berkeley Medical Journal</title>



  

  
  
  <meta http-equiv="content-language" content="English" />

  
  <meta name="description" content="ISSUES Berkeley Medical Journal--Berkeley undergraduate science, medicine, and health journalism." />

  
  <meta name="keywords" content="Issues, berkeley, university, california, journalism, science, medicine, undergraduate, journal, ISSUES Berkeley Medical Journal, Issues Berkeley" />

  
  <meta name="owner" content="ISSUES Berkeley Medical Journal" />

  
  <meta name="revisit-after" content="20 days" />

  
  <meta name="rating" content="General" />

  
  <meta name="robots" content="all" />

  
  <link rel="stylesheet" type="text/css" href="../style.css" /></head><body>
<div id="container">
<!--

******************************

	Header + Navigation

******************************

-->
<div id="header"><a href="../index.html"><img src="../images/logo.jpg" style="border: 0px solid ; float: left; width: 246px; height: 40px;" alt="" align="left" /></a></div>
<div id="nav">
<ul>
  <li><a href="../contactus.html" title="Contact Us">Contact&nbsp;Us</a></li>
  <li><a href="../archive.html" title="Publications">Archive</a></li>
  <li><a href="../courseinfo.html" title="Course Info">Course Info</a></li>
  <li><a href="../aboutus.html" title="About Us">About&nbsp;Us</a></li>
  <li><a href="../index.html" title="Home">Home</a></li>
</ul>
</div>
<!--

******************************

	News Updates Column

******************************

-->
<div id="newsupdate">
<h1>Links and Updates</h1>
<div class="newstitle">.site<span>Navigation*</span></div>
<div id="MainText-left">
<ul>
  <li><a href="../index.html" title="Home">Home</a></li>
  <li><a href="../aboutus.html" title="About Us">About Us</a></li>
  <li><a href="../courseinfo.html" title="Course Info">Course Info</a></li>
  <li><a href="../archive.html" title="Publications">Archive</a></li>
  <li><a href="../staff.html" title="Staff">Staff</a></li>
  <li><a href="../joinus.html" title="Opportunities">Join Us<br />
    </a></li>
  <li><a href="../advertise.html" title="Advertisements">Advertise</a></li>
  <li><a href="../contactus.html" title="Contact Us">Contact Us</a></li>
</ul>
</div>
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<div class="newstitle"><span><br />
</span></div>
<br />
<p><b><br />
<br />
</b></p>
<div class="newstitle"><span><b><br />
</b></span></div>
<b><br />
</b>
<p><b><b><br />
<br />
<br />
<a href="../../external.html?link=http://www.ocf.berkeley.edu/">
<br />
</a> </b></b></p>
</div>
<!--

******************************

   Welcome Message IMG+TEXT

******************************

-->
<div class="rightcontainer">
<div id="welcome"><b><b>science. medicine. health.</b></b></div>
<div id="content">
<h3 style="text-align: center;">The Psueudobulbar Affect<br />
</h3>
<br />
<p style="text-align: center;">Uncontrollable laughter and tears</p>
<p style="text-align: center;">Raimy Boban<br />
</p>

<p style="text-align: center;">Fall 2007<br />
</p>
<p><br />
</p>
<p><small><img style="border: 0px solid ; width: 250px; height: 167px;" alt="pseudobulbar affect pba emotion laughter tear" src="15.1_Boban_R_Pseudobulbar_Affect.jpg.JPG" align="right" hspace="10" vspace="10" />&nbsp;&nbsp;&nbsp;
How would you react to a person who laughs or cries uncontrollably?
Would you recognize that they suffer from the pseudobulbar affect
(PBA), a disorder that affects almost a million Americans?<br />
<br />
&nbsp;&nbsp;&nbsp; PBA is a neurological disorder characterized by the
loss of control over emotional expression, with distinguishing symptoms
such as uncontrollable bouts of laughter or tears. It occurs as a
result of structural damage to the brain, most often associated with
the pathologies of underlying neurological conditions. The underlying
diseases that ultimately cause PBA include amyotrophic lateral
sclerosis (ALS or Lou Gehrig&#8217;s disease), Alzheimer&#8217;s disease,
Parkinson&#8217;s disease, and multiple sclerosis (MS). As noted by Randolph
Schiffer, MD, Texas Tech University Health Sciences Center, and Laura
E. Pope, PhD, Avanir Pharmaceuticals, in a November 2005 article
appearing in the Journal of Neuropsychiatry and Clinical Neurosciences,
10-74 percent of patients with Alzheimer&#8217;s disease have PBA.
Furthermore, 10 percent of MS patients, 11-52 percent of stroke
patients, and 2-49 percent of ALS patients have PBA. <br />
<br />
&nbsp;&nbsp;&nbsp; Normally, cortical and subcortical structures in the
limbic system&#8212;the integrating system that links emotional feelings with
their physical correlates&#8212;send neural impulses to regions of the
cerebellum and brainstem that regulate the expression of emotion. PBA
occurs when these pathways are damaged such that these lower brain
structures can activate emotional expression sans cortical input. The
underlying mechanism of this damage is likely to be glutamatergic
excitotoxicity, a phenomenon in which excess levels of the excitatory
neurotransmitter glutamate overactivate certain neurons, causing a
large influx of calcium ions that ultimately leads to the death of
these cells.<br />
<br />
&nbsp;&nbsp;&nbsp; The similarity of PBA&#8217;s symptoms to those of other
conditions, such as depression, bipolar disorder, and anxiety, makes
PBA difficult to diagnose. However, one diagnostic tool that has shown
some effectiveness is the Pathological Laughing and Crying Scale, a
questionnaire comprising of 18 questions that attempts to quantify
aspects of laughing and crying such as duration and degree of control.
A score of 13 or higher suggests PBA.<br />
<br />
&nbsp;&nbsp;&nbsp; Treatment generally takes the form of
antidepressants in low to moderate doses. Additionally, Avanir
Pharmaceuticals is developing Neurodex®, whose active ingredient is
dextromethorphan (DMX), a common cough suppressant. It is believed that
DMX and quinidine, an enzyme inhibitor, modulate glutamatergic
neurotransmission and can thus potentially prevent excitotoxicity.
Early trials have shown a reduction in the symptoms of PBA, and
Neurodex® is pending approval from the Food and Drug Administration.<br />
<br />
&nbsp;&nbsp;&nbsp; To patients with serious neurological disorders, the
symptoms of PBA are only one of many problems and setbacks they have to
face, but PBA alone is still a socially debilitating condition that
affects the quality of life and relationships. Fortunately, social and
behavioral changes and pharmaceutical treatments can improve the
quality of life for PBA sufferers.<br />
</small></p>


<p><br />
</p>
<h3><b><b><b><b>About the Author<br />
</b></b></b></b></h3>
<p>
</p>
<p><small>Raimy Boban recently graduated in May 2007 with a degree in Molecular and Cell Biology.</small></p>
<p><br />
</p>
<p style="text-align: center;"><a href="15.1_Issue.html"><small>return
to issue</small></a></p>
<p style="text-align: center;"><br />
</p>
</div>
</div>
<div id="footer"> Copyright © 2007 ISSUES Berkeley Medical Journal |
Designed by MockUp | <a href="mailto:bmjwebm@gmail.com">Contact
Webmaster </a><br />
Not an official University publication. Content not necessarily
reflective of UC Berkeley or the ASUC.</div>
</div>

</body></html>